Reference
·Supporting source
Thailand AI drug discovery activity mix (2027 estimate)
Discovery ~28%, clinical-trial AI ~22%
The 2027 Thai AI drug discovery and pharma biotech AI-tooling pool splits across six activities per SCB EIC pharma outlook and operator interviews. AI-led target discovery (oncology, NCD, infectious disease) anchors the largest slice at roughly 28%, followed by clinical-trial AI cohort stratification at 22%, drug repurposing at 18%, AI-tooling vendor licensing (Insilico Pharma.AI, Atomwise AtomNet, Iktos Makya, Exscientia Centaur Chemist) at 14%, AI-CRO and digital-bioservices outsourcing at 12%, and long-tail genomic-data licensing services at roughly 6%. The clinical-trial AI slice grows fastest because foreign-pharma sponsor flow (AstraZeneca, Roche, Pfizer, Novartis, Eli Lilly) ramps faster than upstream discovery cycles can compound.
Figure in context
The 2027 Thai AI drug discovery and pharma biotech AI-tooling pool splits across six activities per SCB EIC pharma outlook and operator interviews. AI-led target discovery (oncology, NCD, infectious disease) anchors the largest slice at roughly 28%, followed by clinical-trial AI cohort stratification at 22%, drug repurposing at 18%, AI-tooling vendor licensing (Insilico Pharma.AI, Atomwise AtomNet, Iktos Makya, Exscientia Centaur Chemist) at 14%, AI-CRO and digital-bioservices outsourcing at 12%, and long-tail genomic-data licensing services at roughly 6%. The clinical-trial AI slice grows fastest because foreign-pharma sponsor flow (AstraZeneca, Roche, Pfizer, Novartis, Eli Lilly) ramps faster than upstream discovery cycles can compound.
Interpretation notes
What this tells you
The 2027 Thai AI drug discovery and pharma biotech AI-tooling pool splits across six activities per SCB EIC pharma outlook and operator interviews. AI-led target discovery (oncology, NCD, infectious disease) anchors the largest slice at roughly 28%, followed by clinical-trial AI cohort stratification at 22%, drug repurposing at 18%, AI-tooling vendor licensing (Insilico Pharma.AI, Atomwise AtomNet, Iktos Makya, Exscientia Centaur Chemist) at 14%, AI-CRO and digital-bioservices outsourcing at 12%, and long-tail genomic-data licensing services at roughly 6%. The clinical-trial AI slice grows fastest because foreign-pharma sponsor flow (AstraZeneca, Roche, Pfizer, Novartis, Eli Lilly) ramps faster than upstream discovery cycles can compound.
What not to do with it
Share of total Thai AI drug discovery and pharma biotech AI-tooling pool at 2027 (THB 14-24B mid-case). Excludes downstream local manufacturing revenue at GPO and Siam Bioscience for AI-discovered compounds.
Related figures
Adjacent numbers that add context without drowning the value.
Thailand AI drug discovery and pharma biotech AI-tooling revenue (2024-2028)
NSTDA BIOTEC, Genome Thailand programme, SCB EIC pharma outlook, PReMA industry profile, foreign-partner disclosures
Genome Thailand WGS cohort buildout (2024-2027)
Ministry of Higher Education, Science, Research and Innovation; NSTDA Genome Thailand programme; NSTDA annual report
Thailand AI drug discovery operator concentration (2027 estimate)
NSTDA BIOTEC; Mahidol Centre for Computational Drug Discovery; Chulalongkorn Health Innovation Hub; Siriraj Centre of Research Excellence; foreign-partner disclosures
BOI Section 8 AI compute credit (effective Q1 2026)
Thailand Board of Investment Section 8 R&D announcement
Foreign-pharma Thailand clinical-trial spend (2025-2027)
AstraZeneca Thailand R&D briefings; Roche Thailand personalised healthcare disclosures; SCB EIC pharma outlook
Thailand AI drug discovery cost-per-validated-target (2026)
NSTDA BIOTEC; Mahidol Centre for Computational Drug Discovery; SCB EIC pharma outlook
Report context
Atlas actors in this figure's reports
Profiles covered in the report that cite this number.